Elexacaftor/Tezacaftor/Ivacaftor Improved Clinical Outcomes in a Patient with N1303K-CFTR Based on In Vitro Experimental Evidence

Am J Respir Crit Care Med. 2021 Nov 15;204(10):1231-1235. doi: 10.1164/rccm.202101-0090LE.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Aminophenols / therapeutic use
  • Benzodioxoles / therapeutic use
  • Child
  • Cystic Fibrosis / drug therapy*
  • Cystic Fibrosis Transmembrane Conductance Regulator / drug effects*
  • Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
  • Drug Combinations*
  • Female
  • Gene Expression Regulation / drug effects*
  • Humans
  • Indoles / therapeutic use
  • Male
  • Middle Aged
  • Mutation / drug effects*
  • Pyrazoles / therapeutic use
  • Pyridines / therapeutic use
  • Pyrrolidines / therapeutic use
  • Quinolones / therapeutic use
  • Young Adult

Substances

  • Aminophenols
  • Benzodioxoles
  • Drug Combinations
  • Indoles
  • Pyrazoles
  • Pyridines
  • Pyrrolidines
  • Quinolones
  • Cystic Fibrosis Transmembrane Conductance Regulator